Sufferers in the UK from multiple sclerosis and possibly rheumatoid arthritis, will welcome the news that they will soon be able to obtain an unlicensed, cannabis-based medicine on prescription to treat their illness. The British Home Office wi
The U.S. Food and Drug Administration are investigating the deaths of 12 children in Japan who took Roche's flu-fighting drug Tamiflu.The U.S. regulators say it is difficult to tell whether the dr
If many seniors are scratching their heads about the new Medicare prescription drug plan, so are the experts. "A prescription for confusion" is how Richard L. Kaplan, a professor of law at the Univer
Ministers have accepted the advice of the Committee on Safety of Medicines (CSM) that simvastatin 10mg (Zocor Heart Pro) could be safely sold through pharmacies to reduce the risk of a first major coronary event in people likely to be at a moderate risk
The U.S. Food and Drug Administration (FDA) is recommending new restrictions on the asthma drug Advair. Advair, marketed in the UK as Seretide, is drug manufacturer GlaxoSmithKline's most popular
In a survey of approximately 930,000 ambulatory care patients, researchers from the Department of Ambulatory Care and Prevention (of Harvard Medical School and
The Indonesian Health Minister Siti Fadilah Supari has announced that the Ministry of Health has been given special rights from drug company Roche, maker of the bird flu drug Tamiflu, to produce the drug.The minister says it has not as yet been
A government panel in Taiwan has decided that the anti bird flu drug Tamiflu can be produced there without permission from the Swiss drug maker Roche AG, if supplies of the medicine run out.According to the Intellectual Property Office the prod
Indonesian President Susilo Bambang Yudhoyono says the authorities there will cooperate with the U.S.-based Baxter International to produce human vaccines for the H5N1 bird flu virus.President Yudhoyono says that Baxter has offered the option o
Major drug company GlaxoSmithKline is hoping to develop an experimental AIDS vaccine by "piggy-backing" on a shot against measles.A collaboration between Europe's biggest drug maker and France's
Mr. Pien will speak on the value of influenza vaccine in protecting health, the importance of raising awareness of the benefits of vaccination, and the need to prepare for an influenza pandemic.
Mr. Pien will also reiterate Chiron's expectation, as stated in the company's August 26, 2004, press release, that it will supply between 46 million and 48 million Fluvirin(R) influenza virus vaccine doses to the U.S. market for the 2004-2005 influenza season, beginning in early October. The planned late-season delivery of 2 million Fluvirin doses for a national stockpile held by the U.S. Centers for Disease Control and Prevention (CDC), not included in the totals above, remains on schedule as well. Since its August announcement, Chiron has worked closely with government agencies to keep them informed of its retesting process. The results of the confirmatory testing to date are consistent with the company's shipping expectations. Following compilation and formal sign-off of its test data, Chiron expects to complete its discussions with regulatory authorities and proceed with releasing Fluvirin to the U.S. market in early October.
A Committee announcement of today's hearing states that the CDC estimates that 6 of every 10 seniors received a flu shot last year, and that federal health officials have established a goal of vaccinating at least 90 percent of seniors by 2010. The hearing coincides with National Adult Immunization Awareness Week, which runs from September 26 through October 2.
In submitted testimony to the Committee, Mr. Pien stated, "Chiron has invested heavily in ensuring that the United States has a supply of influenza vaccine in interpandemic years, which will contribute to protecting the elderly against morbidity and mortality due to the disease. Chiron is committed to the U.S. influenza market and working with government to protect the population, as it continues to age, against influenza as well as to position the United States for preparedness for a global influenza pandemic."
As October and November are the primary months when influenza vaccine is given, the impact of Chiron's shipment delay on the 2004-2005 influenza vaccination season should be minimal. Furthermore, as in past years, the CDC urges continuation of influenza vaccination into December and beyond, given vaccine availability.
To learn more about the hearing, view it via webcast, or read the testimony, please visit http://aging.senate.gov. A live audiocast of the hearing may also be available on the C-SPAN website at http://www.capitolhearings.org. Mr. Pien's testimony will follow that of witnesses representing the CDC and the National Institute of Allergies and Infectious Disease, among others.
According to the CDC, about 5 to 20 percent of the U.S. population contracts influenza each year. Vaccination not only decreases the risk of illness for the vaccine recipient but also helps prevent the spread of the influenza virus and limits its role in the potential development of life-threatening complications. CDC statistics show that, in an average year in the United States, influenza causes more than 200,000 hospitalizations and kills 36,000 people, primarily in ages 65 and older.
Influenza, a contagious disease caused by the influenza virus, affects the respiratory tract, often resulting in symptoms in the nose, throat and lungs, as well as fever, headache, tiredness and body aches. It can also lead to complications such as pneumonia, bronchitis, or sinus and ear infections or exacerbate chronic conditions.
Influenza vaccination provides protection from influenza within about two weeks of administration and may last for as long as a year. The vaccine protects 70 to 90 percent of vaccinated people from contracting influenza, and vaccinated people who do contract influenza generally develop milder cases than unvaccinated people. Influenza vaccines, the majority of which are made from inactivated (killed) influenza strains, are updated each year to address changes in the viruses. People who are allergic to eggs, who have had a severe reaction to an influenza shot in the past, or who have previously developed Guillain-Barre syndrome in the six weeks after receiving an influenza vaccination should consult their doctors before receiving influenza vaccination.
http://www.chiron.com